Schedule of Segment Information |
The
following table is representative of revenue and significant expense categories regularly provided to the CODM when managing the Company’s
single reporting segment (in thousands):
Schedule of Segment
Information
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| |
Three Months
Ended | | |
Six Months
Ended | |
| |
June
30, | | |
June
30, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
Revenues | |
$ | 422 | | |
$ | - | | |
$ | 619 | | |
$ | - | |
Program expenses (1) | |
| | | |
| | | |
| | | |
| | |
Clinical trial studies (1) | |
| 539 | | |
| 604 | | |
| 1,209 | | |
| 1,320 | |
Manufacturing development,
RenovoCath (1) | |
| 383 | | |
| 188 | | |
| 720 | | |
| 225 | |
Program expenses (1) | |
| 383 | | |
| 188 | | |
| 720 | | |
| 225 | |
Other research and development
expenses | (1) |
| 78 | | |
| 13 | | |
| 204 | | |
| 16 | |
Non-program expenses (2) | |
| 998 | | |
| 1,105 | | |
| 2,104 | | |
| 1,992 | |
Personnel compensation and related expenses,
including share-based compensation | |
| 1,102 | | |
| 1,124 | | |
| 2,170 | | |
| 1,957 | |
Other
segment items (3) | |
| 217 | | |
| (645 | ) | |
| (473 | ) | |
| (2,045 | ) |
Net loss | |
$ | (2,895 | ) | |
$ | (2,389 | ) | |
$ | (5,315 | ) | |
$ | (3,465 | ) |
|
(1) |
Includes
external research expenses, clinical studies, manufacturing development and non-recurring engineering costs, professional and consulting,
regulatory, and trade shows. |
|
(2) |
Includes
selling, general and administrative expenses for professional and consulting expenses, audit fees, board fees, legal expenses, insurance
expenses, travel, and other office expenses. |
|
(3) |
Includes
interest income and interest expense and gain recognized on the fair value of common stock warrant liability. |
|